Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMMELA: Pembrolizumab plus Lenvatinib in Recurrent Malignant Pleural Mesothelioma
NCT04287829Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in malignant pleural mesothelioma (MPM), sponsored by Netherlands Cancer Institute. Started Mar 2021; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04287829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287829.